Molecular Partners Publishes MP0317 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Molecular Partners announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenvironment. MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein, which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. The peer-reviewed paper published by Steehgs et al., entitled "Tumor-localized CD40 agonism with MP0317, a FAPxCD40 DARPin, reprograms the tumor microenvironment - results of a Phase 1 monotherapy study", reports the positive results from the completed Phase 1 dose escalation study of MP0317. The comprehensive biomarker data confirm proof-of-mechanism for MP0317, including tumor-localized activation of the CD40 pathway and evidence of TME remodeling in patients with advanced solid tumors. MP0317 displayed a favorable safety profile up to the highest tested dose and serum pharmacokinetics confirmed suitability for dosing either weekly or every three weeks. Of the 46 patients in the study, one patient achieved an unconfirmed partial response and 14 patients stable disease in this heterogeneous population with advanced diseases. Data were presented at the 2024 Annual Meetings of the American Society of Clinical Oncology and of the Society for Immunotherapy of Cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.003
Low
8.00
Averages
10.00
High
12.00
Current: 4.003
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
Molecular Partners Q1 Earnings Miss Expectations
- Earnings Performance: Molecular Partners reported a Q1 GAAP EPS of -$0.67, missing expectations by $0.25, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company holds approximately $365.6 million in cash, cash equivalents, and marketable securities, ensuring sufficient operational funding for the coming years.
- Operational Outlook: Based on current operating assumptions, the company anticipates that its cash and equivalents will support planned operations into the second quarter of 2029, reflecting a degree of financial stability.
- Historical Performance Review: In Q4 2025, Molecular Partners reported a GAAP EPS of -CHF1.65, beating expectations by CHF0.32, indicating some volatility in the company's past financial performance.
See More
Molecular Partners to Present at Scientific Conferences
- Conference Schedule: Molecular Partners will present its clinical-stage Radio-DARPin candidate MP0712 at the NIH National Cancer Institute Small Cell Lung Cancer Consortium Meeting on May 6-7, 2026, showcasing its potential in targeted radiotherapy for small cell lung cancer.
- Clinical Progress Presentation: At the 22nd Annual PEGS Boston from May 11-15, 2026, the company will discuss advancements in Radio-DARPin therapeutics, from preclinical insights to clinical development, highlighting its innovative applications in cancer treatment.
- First Human Data Sharing: The company will share first-in-human data on MP0712 at the Antibody & Engineering Therapeutics conference on May 29, 2026, exploring its applications in targeted alpha therapy and furthering the development of future candidates.
- Commitment to Technological Innovation: Molecular Partners is dedicated to developing next-generation DARPin therapeutics aimed at addressing medical challenges that other treatment modalities cannot readily tackle, demonstrating its leadership in the biotechnology sector.
See More
Positive Phase 1 Data for MP0317 in Cancer Treatment
- Clinical Trial Results: MP0317 demonstrated a favorable safety profile in a Phase 1 trial, with 1 out of 46 patients achieving an unconfirmed partial response and 14 patients showing stable disease, indicating its potential in treating advanced cancers.
- Tumor Microenvironment Modulation: By targeting fibroblast activation protein (FAP) to locally activate the CD40 pathway, MP0317 may enhance efficacy while reducing systemic toxicity, showcasing its significant role in tumor microenvironment remodeling.
- Phase 2 Clinical Study Initiation: An investigator-initiated Phase 2 trial for cholangiocarcinoma has commenced, aiming to enroll 75 patients to compare the effects of MP0317 combined with standard treatment, with the goal of improving the 12-month progression-free survival rate.
- Future Development Prospects: Researchers believe that combining MP0317 with immune checkpoint inhibitors will further enhance its clinical benefits, supporting its potential application in cancer treatment.
See More
Molecular Partners Unveils First Logic-Gated Switch-DARPin T Cell Engager Candidate
- New Candidate MP0632: Molecular Partners has introduced MP0632, a logic-gated Switch-DARPin T cell engager targeting tumors co-expressing MSLN and EpCAM, with preclinical data indicating significant tumor regression, highlighting its potential in treating ovarian cancer and other solid tumors.
- Enhanced Safety and Efficacy: MP0632 achieves efficient tumor cell killing through CD2 co-stimulation while maintaining a low cytokine release profile, demonstrating a favorable therapeutic window that could offer safer treatment options for patients.
- Innovative Computational Workflow: The company presented a computational workflow designed to identify and prioritize tumor-associated antigen pairs, enhancing tumor selectivity and safety, thereby laying a strong foundation for the development of next-generation multispecific immunotherapies.
- Molecular Characteristics of MP0712: MP0712, the first 212Pb-based Radio-DARPin candidate, exhibits high affinity binding to DLL3, and is expected to facilitate sustained tumor uptake through repeated DLL3 internalization-replenishment, supporting its application in treating small cell lung cancer.
See More
Molecular Partners Reports FY 2025 Financial Results with Significant Losses
- Revenue and Loss Overview: Molecular Partners reported no revenue for FY 2025, down from CHF 5 million in 2024, resulting in an operating loss of CHF 58.1 million, although this represents an improvement from CHF 61.2 million in 2024, indicating efforts in cost management.
- Net Financial Loss: The company recorded a net financial loss of CHF 3.5 million in 2025, contrasting sharply with a net financial gain of CHF 7.2 million in 2024, highlighting significant financial challenges that may impact future funding capabilities.
- Cash Flow and Asset Status: As of December 31, 2025, cash and cash equivalents decreased to CHF 93.1 million, down CHF 56.3 million from the end of 2024, reflecting ongoing cash outflow pressures, although it is projected to sustain operations until 2028.
- Employee and R&D Investment: The company employed 134 full-time equivalents as of 2025, with 81% engaged in R&D functions, demonstrating a commitment to innovation despite financial hurdles, indicating a strategic focus on long-term technological advancements.
See More
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
Molecular Partners Q1 Earnings Miss Expectations
- Earnings Performance: Molecular Partners reported a Q1 GAAP EPS of -$0.67, missing expectations by $0.25, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of March 31, 2026, the company holds approximately $365.6 million in cash, cash equivalents, and marketable securities, ensuring sufficient operational funding for the coming years.
- Operational Outlook: Based on current operating assumptions, the company anticipates that its cash and equivalents will support planned operations into the second quarter of 2029, reflecting a degree of financial stability.
- Historical Performance Review: In Q4 2025, Molecular Partners reported a GAAP EPS of -CHF1.65, beating expectations by CHF0.32, indicating some volatility in the company's past financial performance.
See More
Molecular Partners to Present at Scientific Conferences
- Conference Schedule: Molecular Partners will present its clinical-stage Radio-DARPin candidate MP0712 at the NIH National Cancer Institute Small Cell Lung Cancer Consortium Meeting on May 6-7, 2026, showcasing its potential in targeted radiotherapy for small cell lung cancer.
- Clinical Progress Presentation: At the 22nd Annual PEGS Boston from May 11-15, 2026, the company will discuss advancements in Radio-DARPin therapeutics, from preclinical insights to clinical development, highlighting its innovative applications in cancer treatment.
- First Human Data Sharing: The company will share first-in-human data on MP0712 at the Antibody & Engineering Therapeutics conference on May 29, 2026, exploring its applications in targeted alpha therapy and furthering the development of future candidates.
- Commitment to Technological Innovation: Molecular Partners is dedicated to developing next-generation DARPin therapeutics aimed at addressing medical challenges that other treatment modalities cannot readily tackle, demonstrating its leadership in the biotechnology sector.
See More
Positive Phase 1 Data for MP0317 in Cancer Treatment
- Clinical Trial Results: MP0317 demonstrated a favorable safety profile in a Phase 1 trial, with 1 out of 46 patients achieving an unconfirmed partial response and 14 patients showing stable disease, indicating its potential in treating advanced cancers.
- Tumor Microenvironment Modulation: By targeting fibroblast activation protein (FAP) to locally activate the CD40 pathway, MP0317 may enhance efficacy while reducing systemic toxicity, showcasing its significant role in tumor microenvironment remodeling.
- Phase 2 Clinical Study Initiation: An investigator-initiated Phase 2 trial for cholangiocarcinoma has commenced, aiming to enroll 75 patients to compare the effects of MP0317 combined with standard treatment, with the goal of improving the 12-month progression-free survival rate.
- Future Development Prospects: Researchers believe that combining MP0317 with immune checkpoint inhibitors will further enhance its clinical benefits, supporting its potential application in cancer treatment.
See More
Molecular Partners Unveils First Logic-Gated Switch-DARPin T Cell Engager Candidate
- New Candidate MP0632: Molecular Partners has introduced MP0632, a logic-gated Switch-DARPin T cell engager targeting tumors co-expressing MSLN and EpCAM, with preclinical data indicating significant tumor regression, highlighting its potential in treating ovarian cancer and other solid tumors.
- Enhanced Safety and Efficacy: MP0632 achieves efficient tumor cell killing through CD2 co-stimulation while maintaining a low cytokine release profile, demonstrating a favorable therapeutic window that could offer safer treatment options for patients.
- Innovative Computational Workflow: The company presented a computational workflow designed to identify and prioritize tumor-associated antigen pairs, enhancing tumor selectivity and safety, thereby laying a strong foundation for the development of next-generation multispecific immunotherapies.
- Molecular Characteristics of MP0712: MP0712, the first 212Pb-based Radio-DARPin candidate, exhibits high affinity binding to DLL3, and is expected to facilitate sustained tumor uptake through repeated DLL3 internalization-replenishment, supporting its application in treating small cell lung cancer.
See More
Molecular Partners Reports FY 2025 Financial Results with Significant Losses
- Revenue and Loss Overview: Molecular Partners reported no revenue for FY 2025, down from CHF 5 million in 2024, resulting in an operating loss of CHF 58.1 million, although this represents an improvement from CHF 61.2 million in 2024, indicating efforts in cost management.
- Net Financial Loss: The company recorded a net financial loss of CHF 3.5 million in 2025, contrasting sharply with a net financial gain of CHF 7.2 million in 2024, highlighting significant financial challenges that may impact future funding capabilities.
- Cash Flow and Asset Status: As of December 31, 2025, cash and cash equivalents decreased to CHF 93.1 million, down CHF 56.3 million from the end of 2024, reflecting ongoing cash outflow pressures, although it is projected to sustain operations until 2028.
- Employee and R&D Investment: The company employed 134 full-time equivalents as of 2025, with 81% engaged in R&D functions, demonstrating a commitment to innovation despite financial hurdles, indicating a strategic focus on long-term technological advancements.
See More
